| Names | |
|---|---|
| Preferred IUPAC name | (2S)-2-amino-N-(5-amino-5-oxopentyl)-3-carbamoylpropanamide |
| Other names | L-Alanyl-L-Glutamine Ala-Gln Sustamine Dipeptiven Ala-GLN |
| Pronunciation | /əˈlæ.nɪl ˈɡluː.təˌmiːn/ |
| Identifiers | |
| CAS Number | 39537-23-0 |
| Beilstein Reference | 3921285 |
| ChEBI | CHEBI:85174 |
| ChEMBL | CHEMBL1233252 |
| ChemSpider | 16132 |
| DrugBank | DB04457 |
| ECHA InfoCard | 100.215.093 |
| EC Number | EC 2.3.2.2 |
| Gmelin Reference | 87118 |
| KEGG | C14272 |
| MeSH | D000596 |
| PubChem CID | 144538 |
| RTECS number | TC8650000 |
| UNII | A09O20458K |
| UN number | UN3334 |
| CompTox Dashboard (EPA) | DTXSID7046238 |
| Properties | |
| Chemical formula | C8H15N3O4 |
| Molar mass | 290.301 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 0.77 g/cm3 |
| Solubility in water | soluble |
| log P | -3.64 |
| Vapor pressure | Negligible |
| Acidity (pKa) | pKa1 = 2.17, pKa2 = 9.13 |
| Basicity (pKb) | 6.19 |
| Refractive index (nD) | 1.514 |
| Viscosity | Viscosity: 1.006 mPa·s (25 °C, 20% solution) |
| Dipole moment | 12.52 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 365.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -1434.7 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3735 kJ/mol |
| Pharmacology | |
| ATC code | B05BA01 |
| Hazards | |
| Main hazards | Not a hazardous substance or mixture. |
| GHS labelling | GHS07; Signal word: Warning; Hazard statements: H315, H319, H335; Pictograms: exclamation mark |
| Pictograms | GHS07 |
| Signal word | No signal word |
| Hazard statements | Not a hazardous substance or mixture according to the Globally Harmonized System (GHS) |
| Precautionary statements | Keep container tightly closed. Store in a cool, dry place. Avoid breathing dust. Use only with adequate ventilation. Wash thoroughly after handling. |
| NFPA 704 (fire diamond) | 0-0-0 |
| LD50 (median dose) | LD50 (median dose): > 5,000 mg/kg (rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | Not established |
| REL (Recommended) | 0.3 g/kg |
| IDLH (Immediate danger) | No IDLH established. |
| Related compounds | |
| Related compounds | Glutamine Alanine Glycyl-glutamine L-alanyl-L-glutamine Dipeptides Glutamyl-alanine |
| Property | Details |
|---|---|
| Product Name | Alanyl Glutamine |
| IUPAC Name | (2S)-2-(2-Aminopropanamido)-4-carbamoylbutanoic acid |
| Chemical Formula | C8H15N3O4 |
| CAS Number | 39537-23-0 |
| Synonyms & Trade Names | L-Alanyl-L-glutamine; Ala-Gln; L-Glutamine, N2-L-alanyl-; Sustamine (trademarked formulation in some regions) |
| HS Code & Customs Classification | 2924.19 (Amides and their derivatives; based on regional customs reference) |
Alanyl glutamine appears in both pharmaceutical and nutritional formulation sectors. The grade selection responds directly to application. For parenteral nutrition, low impurity content is paramount, with batch consistency and endotoxin control forming the backbone of release criteria. Nutritional-grade material accepts broader impurity thresholds but still requires screening for peptide-related side products during synthesis. Approaches to specifications differ by region and end-market regulation.
Alanyl glutamine’s chemical characteristics arise from its dipeptide structure, offering enhanced solubility and improved stability over free glutamine. Typical industrial production methods aim for a dry, free-flowing powder, controlling particle size based on formulation needs. Pharmaceutical-grade material may require additional sieving to limit oversized or undersized fractions, responding to downstream process sensitivity—such as reconstitution time—especially in injectable formats.
Manufacturers prioritize pharma-grade amino acid inputs to minimize origin-related contamination and batch-to-batch profile changes. Different synthetic routes—enzymatic, solution-phase, or solid-phase—lead to distinct impurity profiles. Route is selected on both cost considerations and waste management. Enzymatic routes have fewer racemization concerns, while solution-phase synthesis enables larger batch sizes but may require intensive chromatographic purification steps.
Purification aligns with targeted grade. For parenteral use, ultrafiltration, ion-exchange chromatography, or preparative HPLC may be introduced to reduce residual starting materials and side peptide formation. In-process HPLC, amino acid analysis, and moisture determination guide every manufacturing stage, giving early warning of synthesis drift or contaminant introduction. Consistency in pH during coupling and deprotection is tracked as part of in-process control due to the high reactivity of the activated species in peptide bond formation.
Hydrolysis of either component, incomplete coupling, and racemization form the most common impurity sources. Higher temperature or prolonged activation exacerbates side-chain modifications, raising the need for rapid process cycles and temperature control. Batch records document every input and condition for full traceability in case of deviation. End-of-line analysis emphasizes peptide purity, related substance profile, microbial contamination, and identity confirmation through NMR or mass spectrometry for pharma-grade lots. Nutritional batches may use streamlined analytics depending on customer requirements.
Authorities classify alanyl glutamine under peptide/amino acid derivatives; HS coding depends on intended end-use declaration. Customs require clear documentation of composition and purity to distinguish from simple amino acid blends, reducing risk of shipment holds. Exporters prepare dossier data reflecting manufacturing and analytical flow to demonstrate compliance at border inspection points.
In bulk production, Alanyl Glutamine generally appears as a white to off-white crystalline powder, though some lots may present a faint odor due to trace synthesis residuals. Granule size, dust content, and flow may change based on drying and milling setup. Melting point typically falls in a narrow grade-dependent range; uncontaminated material exhibits no discoloration at room temperature. Moisture-sensitive grades can incur texture and caking changes from air exposure, an effect that intensifies above typical storage humidity.
Standard process-grade Alanyl Glutamine remains chemically stable in sealed, low-humidity conditions. Unsealed exposure, especially at elevated temperature or moisture, can promote hydrolysis or degrade organoleptic qualities. Reaction to chemical reducing or oxidizing agents depends on batch residuals level and buffer pH. Off-grade purity may increase reactivity, shifting storage recommendations.
Alanyl Glutamine dissolves readily in water, with solubility influenced by pH, mixing speed, and water quality. Dusting grades or micronized forms hydrate faster, while large crystals may require extended mixing. Processing areas generally use filtered deionized water under temperature control to avoid excess foaming, undissolved clumps, or off-odor when prepping feed or pharma-grade solutions. Product stability in solution changes with concentration and room temperature holding time.
Specifications are defined for food, pharma, and feed grades. Concentration of active ingredient, moisture, and identifiable impurities differ between these, set by end-use and local regulatory frameworks. Particle size distribution, solubility speed, and microbiological status serve as additional sorting criteria for customer lots.
Impurity acceptance limits vary between pharma, food, and feed grades. By-products include residual parent amino acids, dipeptide isomers, and process residuals. Internal batch logs track each synthesis series for off-pathway contaminants, which arise from overreaction, side-chain modifications, or raw material breakdown. Final impurity control integrates results from HPLC, amino acid analysis, and spectroscopic checks. The release threshold for each species follows customer and pharmacopoeial demands.
Physical and chemical properties are measured by in-house validated methods referencing USP, EP, or local standard methods. Analytical technique selection takes into account the grade, regulatory status, and specific impurity risk. Chromatography and specific enzymatic assays are routine, with identity confirmed against certified reference material. Batch approval may require third-party verification for regulated markets.
Key inputs are pharmacopeial grade L-alanine and L-glutamine, sourced from audited suppliers. Procurement focuses on certificate-backed amino acids with known origins and consistent impurity loads. Each intake lot is profiled prior to use, with non-conforming materials segregated.
Alanyl Glutamine is produced through a peptide coupling of L-alanine and L-glutamine. Route selection weighs pH control, side reaction minimization, and overall yield. Common coupling agents are chosen for their residue profile and environmental handling. Some processes utilize proprietary catalysts or specific temperature profiles to manage epimerization and unwanted polymerization.
Critical steps include in-process pH adjustment, temperature sequencing, and intermediate purification typically by crystallization or membrane separation. Recycling of solvent streams is balanced against cross-contamination risk. Multiple in-process checks validate intermediate conversion, regulate residual starting material, and monitor for unintended by-products. Batch-wise adjustments ensure reproducible bulk quality and impurity compliance.
Batch release depends on multi-point testing: identity, assay, impurity scan, moisture, and solubility, with periodic advanced characterization by mass spectrometry or NMR. Batch-to-batch data is logged for trend analysis and deviation management. Customer-specific paperwork accompanies each consignment, referencing grade, lot batch, and custom acceptance criteria where required.
In downstream processes, Alanyl Glutamine can undergo hydrolysis, yielding the constituent amino acids. Reaction rate depends on pH, temperature, and solvent exposure. Avoiding uncontrolled hydrolysis in formulation processes guides excipient choice and solution holding protocols. Enzymatic breakdown is also relevant in bio-catalytic applications.
Catalysts and reaction aids are chosen case-by-case, based on required conversion and downstream requirements. Temperature control throughout synthesis and storage affects both reaction speed and product stability. Solvent choice swings between water and buffered organics depending on the end-use isolation strategy.
Chemical or enzymatic modification produces derivatives for nutraceutical, clinical nutrition, and specialty peptide markets. Typical offshoots include short-chain analogs and protected forms, customized for regional market demands. Each modification pathway is assessed for scalability and compatibility with established purification practices.
Stable lots maintain appearance and function in tightly sealed, moisture-protected packaging, away from direct sunlight and excess temperature swings. Humidity above defined standards leads to clumping and hydrolysis risk, shortening shelf life for sensitive applications. Nitrogen flush and desiccant inclusion are practical for pharma and high purity products.
Standard container choices include food- or pharma-grade HDPE, PP, or multilayer foil packs. Migration tests dictate container permission for critical applications. Reused or residual-stained containers raise risk of off-batch cross-contamination.
Well-stored batches retain properties over the labeled shelf period. Signs of degradation include color darkening, odor change, moisture gain, and solubility drop. Overage is allocated to counter end-of-life losses for critical supply chains and long-haul shipments.
GHS classification reflects low acute oral toxicity and minimal irritancy for standard grades. Dust generation during handling can irritate airways if workplace controls lapse. Hazard labelling aligns with national chemical safety codes and batch impurity content.
Safety recommendations anchor on dust control, minimization of skin and eye contact, and avoidance of inhalation during bulk transfer. Eye washes and local exhaust ventilation remain standard in production transfer and packing lines.
Acute and chronic toxicity is considered low, based on animal and cell model studies. Pharmacopeia monographs and GRAS assessments underpin food and clinical grade certifications. Feed grade toxicity follows local regulatory position statements and in vivo study review.
Handling guidelines adjust to facility controls and potential batch impurity. Exposure minimization follows plant hygiene rules and site-specific risk review. Proper dust extraction, personnel protection, and container management form the foundation for safe workplace operation.
Annual output for Alanyl Glutamine hinges on available fermentation, downstream purification, and lyophilization infrastructure. Feedstock stabilization and purification throughput often determine short-term plant rates. In years where amino acid starting materials (mainly L-alanine, L-glutamine) see constrained supply, output can pinch. The availability for contract manufacturing or special grades typically aligns with planned expansions or new fermentation vessel deployment, which require several months’ lead time. For routine grades, production cycles are planned to batch demands and align with sector-specific consumption, including pharmaceutical and clinical nutrition markets.
Batch-based manufacturing dictates delivery timeframes. Typical lead times for standard grades range from 2 to 6 weeks, depending on purification and drying schedules. Custom grades or dedicated campaigns, where trace impurity levels or tailored physical properties are critical, lead times increase due to validation and QC release. MOQs depend on customer grade requirements and packaging format; industrial bulk starts at drum-scale, while pharmaceutical or clinical orders often require validation at lower batch volumes, subject to quality clearance and customer approval processes.
Packaging form (fiber drums, foil-lined sacks, HDPE bottles) is determined by shipment size, customer process flow, and regulatory requirements. Oxygen and moisture-sensitive applications often require nitrogen-flushed liners or tamper-evident closures, especially for parenteral or clinical grades. Packaging is validated for material compatibility and leachable profiles depending on the downstream formulation environment.
Typical commercial terms follow FOB or CIF port under Incoterms standards, with credit periods subject to customer history and transaction value. Cold-chain or temp-controlled shipping applies to higher sensitivity grades or in-transit risk profiles. Payment schedules are matched to pre-shipment sample approval and bulk release protocols. Document preparation, including compliance declarations and CoA/CoO paperwork, is integrated into the transit cycle.
Price consists mostly of amino acid substrate costs, energy consumption (fermentation, chromatography, lyophilization), and solvent/purification media. Wholesale cost variance is most sensitive to L-alanine and L-glutamine feedstock shifts, which themselves react to upstream agricultural fermentation supply, energy rates, and occasional supply shocks in global glycine/glutamate markets. Waste stream neutralization and solvent recovery expenses, tied to local environmental regulations, have risen in several production geographies. Regulatory compliance pushes (including updated cGMPs, REACH, or USP monograph alignment) add to operational expenditure.
Pharmaceutical, clinical, and injectable grades command different release specifications for endotoxins, microbial limits, and residual solvent profiles. These drive up production costs due to higher frequency of purification cycles, extended QC, and batch segregation. Packaging certification, especially for clinical market destinations in the US/EU, adds cost due to traceability and leachable/extractable analysis requirements. Technical/industrial grades follow less stringent protocols, lowering both batch discards and compliance input.
Growth in clinical nutrition and parenteral product manufacturing, especially in North America, Western Europe, and segments of Asia, supports overall demand. Major supply comes from East Asia (China, Japan) and some Western European plants that specialize in clinical APIs. Local capacity expansions in India have slightly rebalanced regional bargaining in the last two price cycles. The market remains consolidated due to heavy process validation and plant certification requirements, which limits rapid new capacity entry.
The US and EU see significant volumes reserved for regulated clinical and pharma uses, so importers demand well-documented cGMP compliance and lot traceability. Japan, a large clinical nutrition market, has domestic producers meeting niche quality needs and tight specifications. India’s growth focuses on cost-sensitive buyers, with variable document requirements. China dominates supply for technical and food/nutritional grades, and is building more pharma-grade export capability, subject to regulator spot inspections and ongoing supplier audits.
Pricing through 2026 is expected to remain closely tied to fermentation substrate expenses, utility tariffs, and global regulatory stringency. If L-alanine or L-glutamine spot markets remain stable, no major upward shocks are expected. Escalating compliance and energy costs in high-value markets may lift pharma-grade values 5–10% over 2024 levels. Data is derived from quarterly peer market audits, trade association benchmarks, and direct feedback from global end-user forums.
Several Western regulatory bodies raised scrutiny of API plants exporting to regulated markets, tightening documentation and audit frequency. Some producers have added real-time monitoring and in-line impurity profile testing to address batch consistency commentary in end-user audits.
Stricter EU and US guidance on trace metals, residual solvents, and elemental impurity risk assessments now shape batch release logic. Chinese authorities pushed for transparent export certification processes to combat grey-market cross-labeling, directly affecting documentation and shipment workflows.
Manufacturers adjusted by investing in more precise feedstock assays, automating in-process QC integration, and training production teams in newer pharmacopeia method updates. In regions facing supply chain bottlenecks, holding larger strategic stock and implementing secondary sourcing have improved delivery reliability, at the expense of carrying costs. Downward pricing pressure continues for nutritional/industrial grades, but premium, audit-ready batches require ongoing process upgrades and third-party validation, maintaining a split pricing structure by grade and geography.
Production teams supply Alanyl Glutamine across several core sectors. Key applications include parenteral and enteral nutrition, bioprocessing as a cell culture supplement, functional foods and beverages, oral health formulations, and veterinary or animal nutrition. Clinical nutrition end users, particularly in hospital supply chains, have strict traceability and release quality standards. Bioprocessing customers often push requirements on endotoxin, residual solvents, and elemental impurities to limits beyond food or feed grades. Food and beverage formulators prioritize physical consistency, organoleptic neutrality, and compliance with international additive codes. In animal science, volume remains central to planning and logistics, favoring cost-optimized grades.
| Application | Typical Grade(s) | Key Specification Focus | Considerations |
|---|---|---|---|
| Parenteral Nutrition | Injection/Infusion or API Grade | Purity, Endotoxin, Residual Solvents, Elemental Impurities, Microbial Load | Release criteria must match pharmacopoeial standards. Every batch is individually reviewed against both customer and regulatory requirements. |
| Enteral Nutrition & Functional Food | Food/Clinical Nutrition Grade | Purity, Taste/Odor, Particle Size, Allergen Statement | Consistency in flavor and dispersibility affects acceptability in product matrix. |
| Cell Culture & Bioprocess | Cell Culture/Biotech Grade | Low Endotoxin, High Purity, Trace Metals Profile | Most lots pass additional screening for process contaminants relevant to mammalian culture. |
| Oral Health & Sports Supplements | Nutraceutical/Food Grade | Organoleptic Quality, Certificate of Non-GMO/Allergens | Labelling and raw material transparency require supporting documentation. |
| Veterinary & Animal Feed | Feed/Industrial Grade | Bulk Purity, Absence of Prohibited Substances | Specification depends on national or regional feed safety standards. |
Each plant and customer must start from the intended end use. Every sector features its own acceptance criteria: parenteral, enteral, bioprocess, or veterinary. User must delineate clinical from nutritional, and food from feed applications. Technical and regulatory documents must be referenced early in the inquiry stage.
Each region and sector imposes its own compliance grid. Pharmaceutical users refer to compendial monographs, while food producers track international additive registrations or country-specific tolerances. The company's regulatory affairs support can help to match orders with local statutes and documentation demands.
Purity requirements reflect downstream criticality. Injectable and cell culture customers mandate the highest purity profiles. Food and feed use may accept broader tolerance, subject to absence of specific contaminants. The production quality control labs monitor and document impurity levels at each control point, issuing a record with each batch.
Procurement and planning often weigh grade selection against seasonal or campaign volume. Pharma and biotech grades entail higher release costs due to testing and controls, while food and feed grades support larger-scale, cost-driven purchasing. The plant provides pricing and lead time guidance based on current manufacturing slot and raw input availability.
Customers should conduct a practical validation of product grade in their intended end-use scenario. The technical services unit organizes sample dispatch, matching batch records and certificate packs with the requested grade. Application trials often identify if a tighter grade is necessary, or if a less intensive standard could suffice for non-critical downstream processing.
Operating as the actual producer of Alanyl Glutamine requires maintaining robust quality management systems. The facility’s certification status reflects routine audit practices, procedural discipline, and corrective action mechanisms. Certification such as ISO 9001 is upheld through documented systems that direct personnel and process training, oversee validation of cleaning regimes, and ensure traceable production records. Audit trails remain open for review and regulatory inspection, and non-conformance management is treated as a routine part of process governance. Adjustment of the QMS scope occurs when introducing new production equipment or expanding plant capacity, emphasizing traceability and risk assessment along the whole supply chain.
Grade selection (food, clinical, pharma, or industrial) dictates the nature of product certifications. When serving regulated sectors, alignment with regional pharmacopeias such as USP, EP, JP, or ChP is documented via compliance statements and retained analytical batch records. For nutrition-grade or feed-grade material, evidence of absence of restricted substances and compliance with relevant food safety management system standards are maintained. Audit processes verify that critical raw materials, processing aids, and packaging align with intended end-use approvals. No specification is universal—the technical file profile is confirmed batch by batch in accordance with customer-side release protocols and local regulations.
Batch-specific documentation remains accessible through an integrated quality documentation system. Manufacturer-issued batch COAs include all routine assays, key impurity profiles, and trace element data where requested. Where specifications permit, additional test reports—such as microbial limits or residual solvent profiles—are provided. Tailored documentation for customer audits, regulatory filings, or technical reviews is supplied based on mutual confidentiality and disclosure agreements. Technical dossiers include detailed production history, release criteria, and independent third-party testing results when required for new supplier approval or cross-validation.
From a manufacturer’s standpoint, consistent supply of Alanyl Glutamine draws on integrated capacity planning. Plant capacity is structured according to infrastructure investment and real-time order tracking systems. Upscaling or scheduling flexibility can be extended for both forecast-based and spot orders, subject to pre-agreed production slots and technical change management approvals. The cooperation framework involves straightforward pricing mechanics and mutually-agreed volume commitments; it draws lessons from previous production cycles, seasonal demand swings, and core customer requirements. Early access to supply chain disruption mitigation resources can be discussed in custom contingency protocols.
Sourcing reliability relies on verified procurement channels for raw materials, on-site purification system capacity, and validated logistics partners. Critical process steps are continuously monitored, and material trace-back is supported by electronic production records. Downtime risks are minimized by redundant key equipment and cross-trained staff. Supply agreements are typically offered with volume flexibility scaled to assessed annual demand, taking into account actual campaign yields and planned maintenance downtime. Where product grade or purity requirements shift with application area, technical pre-engagement helps forecast specification-based batch allocation.
Technical evaluation samples are handled under a formalized request system. The sample dispatch process integrates with the plant’s small-batch production module; sample reservation and shipment use segregated storage to avoid cross-contamination. Customers specify intended use, grade, and desired tests at the request stage. Each sample shipment includes its batch COA, and additional analytical support can be discussed for trial formulation or scale-up validation. Feedback on sample use feeds directly into technical and quality review meetings, supporting future batch alignment.
Supply relationships are defined in close communication with end users’ operational timelines, order flexibility ranges, and technical onboarding needs. Options extend from fixed-schedule supply through framework agreements to call-off orders, and pilot quantities are managed distinctly from routine batch production. Adjustments in packaging, documentation, labeling, or analytical release can be addressed through technical service support rather than relying solely on standard commercial order channels. Business continuity measures remain subject to technical feasibility, supply chain transparency, and structured risk assessment, all handled internally by the manufacturer’s supply, production, and QA teams.
Ongoing development work in alanyl glutamine centers on process intensification, impurity profile control, and novel grade customization for clinical and industrial applications. Many teams focus on enhancing enzymatic synthesis for increased conversion efficiency and improved scalability, given cost pressures and rising demand for high-purity grades. Raw material selection—especially amino acid feedstock origin—remains a major factor in impurity management and downstream purification complexity.
Within nutritional and clinical sectors, researchers pay close attention to tailoring solubility, bioavailability, and stability profiles to match pharmaceutical, parenteral, and enteral formula requirements. In process development, continuous reactor systems and membrane-enabled separations draw significant interest for reducing solvent consumption and waste generation.
Hospitals and nutrition product manufacturers are increasingly evaluating alanyl glutamine for next-generation infusion solutions and specialized enteral nutrition, particularly for critical illness recovery regimes. Animal nutrition suppliers are exploring feed additive formulations targeted at gut health and stress mitigation, which require robust endotoxin control and residue minimization.
New work in cell culture media highlights alanyl glutamine as a stable glutamine source in vaccine, antibody, and recombinant protein manufacturing, pushing requirements for low byproduct and near-zero bioburden grades.
Controlling dipeptide hydrolysis and maintaining chemical consistency between batches demands robust process discipline and in-process analytical control. Main technical hurdles include eliminating trace-level byproducts such as pyroglutamate, managing racemization, and tuning crystallization to meet solubility and filtration performance targets.
Recent breakthroughs include optimized coupling reagents and engineered enzymatic catalysts, which reduce formation of byproducts and increase overall yield. Novel membrane filtration systems help handle impurity removal—particularly for low-endotoxin grades needed in parenteral applications.
Growth drivers are strongest in clinical nutrition and high-specification biopharma manufacturing, reflecting shifts toward peptide-based formulations and advanced bioprocessing. Typical market models project incremental volume expansion, with a focus on tailored specifications for end-use sectors. Regulatory scrutiny and demand for traceability may create divergent grade requirements across regions and application fields, requiring flexibility in both process and quality release models.
Enzyme-engineered synthesis routes will gain share as cost pressures and demand for high-purity, specialty grades rise. Integrated process analytics, especially real-time monitoring, are becoming standard to deliver consistent impurity profiles. Facilities investing in digital batch tracking and feedstock traceability gain control over long-term quality recordkeeping and process troubleshooting capabilities.
Crystallization and drying system improvements continue to be refined to minimize product losses and support scale-up for both bulk and high-purity lines. Customers increasingly request backward-traceability and transparent raw material documentation as part of product qualification.
Raw material renewable sourcing, water minimization, and solvent recycling remain at the center of internal sustainability initiatives. Newer process designs aim to minimize hazardous reagent use in amidation and coupling steps. Lifecycle analysis of waste streams and energy usage is supported by batch-to-batch impact tracking, especially for European and North American export specifications. Adoption of greener manufacturing logic often depends on investment cycles and the emergence of regulatory incentives.
From technical affairs, we maintain specialized engineer consultation for customers requiring technical clarification on product suitability, compatibility in formulation or process, and compliance against pharmacopeia standards. Technical support activities include impurity profile discussions, documentation support for regulatory filings, and sharing of analytical method performance data based on product batch records.
Support extends to in-depth evaluation of alanyl glutamine integration into customer-specific production streams. For high-purity and low-endotoxin applications, we provide guidance on reconstitution protocols, recommend filtration systems to minimize particle or bioburden load, and share experience on stability expectations under varied process and storage conditions. Feedback loops with R&D teams help adapt product characteristics as downstream manufacturing needs evolve.
Quality assurance teams track customer feedback and batch-specific inquiries to support robust complaint resolution and continuous improvement. Consistent documentation of batch release criteria, traceability to raw material origin, and full transparency during audit requests form the mainstay of our after-sales commitment. Technical personnel remain engaged with customers on long-term supply, stability questions, and requalification support for established product applications.
Our facility manufactures Alanyl Glutamine using controlled fermentation and purification processes designed for consistent result batch after batch. Every production stage operates under closely monitored parameters to maintain the peptide bond integrity. Extensive process validation enables our technical teams to meet strict thresholds for residual solvents, moisture, and related compounds, targeting stable physical properties favored by large-scale formulators and blenders.
Alanyl Glutamine holds recognized value as a high-purity peptide for large-scale preparation of clinical nutrition blends, enteral feeding solutions, and certain bioprocessing buffers. In these segments, buyers count on precise composition and low endotoxin levels, both of which begin at the point of synthesis. We produce to satisfy these critical factors, with documented lot histories for pharmaceutical and industrial customers alike.
Operating as a hands-on manufacturer rather than a distributor, all incoming raw materials undergo systematic QC validation before each production run. In-process controls dovetail with comprehensive finish-product analytics—HPLC, microbiology, heavy metal screens—prior to release. Consistent product standards reduce out-of-spec events and support straightforward traceability during audits or regulatory inspections. This model eliminates the uncertainty sometimes encountered when relying on multi-tiered sourcing channels.
We fill Alanyl Glutamine in lined fiber drums, HDPE kegs, or custom bulk sacks designed to preserve physicochemical stability during storage and transit. We maintain defined fill weights and clear exterior labeling with batch codes and expiry dates, supporting industrial workflows where receiving and inventory protocols demand strict adherence to specification. Fully integrated warehousing allows for flexible shipment schedules and scalable output, supporting procurement cycles ranging from pilot scale to large annual contracts.
Industrial partners benefit from direct access to our process chemists and QC engineers. We assist with transition planning, method validation, and blending trials. For contract manufacturers and product developers, this means reduced time troubleshooting and more rapid progress from trial batches to routine operation. We share documentation on crystallinity, solubility, and pH response curves to support formulation adjustments or downstream process changes.
Operating with clear product stewardship and direct supply, our model streamlines negotiation, simplifies logistics, and reduces the distortion in cost sometimes associated with intermediary markups. Procurement professionals value controlled lead times, batch reservation options, and predictable technical documentation flow. For global distribution customers and direct end-users, stable output and in-house technical resources strengthen risk management in competitive settings where reliability matters most.
Few details matter more to partners in clinical nutrition, biotechnology, or pharmaceuticals than assay value and purity of Alanyl Glutamine. Our team’s approach reflects hands-on knowledge of the product’s role in sensitive downstream applications—from parenteral nutrition to cell culture media. Each production batch reflects our ongoing commitment to reliability and transparency because the expectations on end-use safety and performance set a high bar.
We see purity as both a baseline for safety and as the primary value indicator. For Alanyl Glutamine, we have established a standard that ensures the assay (on dry basis) typically remains at or above 98.0%. This benchmark aligns with accepted pharmacopoeial parameters and reflects the results we routinely see in full-batch quality reports generated at our facility.
It’s not just about a number—it’s about what stands behind it. Our facilities run high-purity synthesis and employ multi-stage purification steps anchored by continuous analytics. Finished lots undergo high-performance liquid chromatography (HPLC) to quantify content and identify trace contaminants. Impurity levels, including related peptides, are tightly controlled and monitored with every production. Environmental factors and raw input quality play a role, so we have invested in both modern filtration and robust source vetting. The outcome: stable and verifiable purity.
We know manufacturers and formulators rely on prompt, accurate assay certificates. Every lot comes with a certificate of analysis, reporting the assay value (dry basis), loss on drying, specific optical rotation, and heavy metals content. Our production process targets a loss on drying value below 0.5% to protect both free-flowing properties and stability. We keep heavy metals below pharmacopoeia limits—lead, arsenic, and mercury are quantitated in every batch, not just by periodic spot checks.
We structure our internal quality system to align with the requirements of major pharmacopoeial agencies and the expectations of end users focused on patient safety or laboratory reproducibility. Our Alanyl Glutamine is manufactured under GMP conditions, subject to full-traceability audits, and released only after meeting in-house and regulatory specifications.
We see demand for detailed impurity profiles and validated analytical methods rising across industries. Our technical team keeps full dossiers on accuracy, repeatability, and instrument calibration. If a customer requests documentation or full impurity curves beyond the certificate of analysis provided, we can supply these records.
Predictability helps our customers keep their own processes efficient. That’s why we focus on minimizing lot-to-lot variation—not just matching a label claim. Regular calibration of HPLC columns and verification with certified reference standards allow us to catch subtle shifts early. Any outliers are investigated at the source, rather than relying solely on end-point analytics.
Questions regarding impurity breakdowns, co-eluting substances, or compliance support are addressed directly by our technical staff. The dialogue between production and end-users is ongoing, ensuring expectations remain aligned and new industry requirements are met. We can provide detailed specification sheets and documentation to support customer audits and regulatory filings.
Our investment in quality control and process transparency stands behind every kilogram shipped. That confidence comes from direct, integrated manufacturing—not a paper trail of suppliers.
Production times for bulk orders take careful planning on our floor. For Alanyl Glutamine, our standard lead time for bulk orders typically ranges between 15 to 25 days from contract confirmation. That estimate covers material sourcing, process scheduling, and rigorous quality inspection. During peak periods, or for orders with custom packaging or specific technical requirements, it is wise to factor in possible extra days for final release. We keep our communication transparent throughout each stage, making sure the expected timeline is clear and updated for every client. If urgent shipping is necessary, our production team reviews feasibility using existing raw material stocks and current line capacity.
Bulk production draws efficiency from scale. For Alanyl Glutamine, the minimum order quantity starts at 500 kilograms per transaction. This baseline allows cost-effective raw material purchasing, optimal batch processing, and reliable quality control in line with industry requirements. Clients ordering several small lots face delays and higher cost per unit compared to consolidated, larger runs. By maintaining a clear minimum, we reduce unnecessary downtime and support stable production schedules.
Production complexity changes with each client’s technical demands. Large pharmaceutical and nutrition customers often require specific grade consistency and documentation. Our experienced technical staff review documentation needs and carton labeling before the first shipment leaves the plant, so orders meet both commercial and regulatory goals each time. For clients with ongoing needs, batch reservation or staged delivery can be arranged out of our finished goods warehouse, supporting project-based or JIT (Just-In-Time) workflows.
Alanyl Glutamine manufacturing relies on strict in-process QC checkpoints as well as final lot inspection. We implement standard release protocols. Each shipment receives a detailed Certificate of Analysis, referencing tested parameters before dispatch. Clients expect consistent purity, solubility, and shelf stability—and we take full responsibility for those targets as the producing plant.
Our technical team works with customers who have special requirements for particle size, packaging, or delivery method. This often involves added planning in molding, filling, or outer packaging. Strong volumes let us provide customized packing configurations, from fiber drums to multi-layer composite sacks. Any added customization can add a few days to the manufacturing timeline, but our direct communication keeps the process smooth and transparent.
Operating as a direct manufacturer, we routinely invest in process automation and expanded capacity to keep pace with global demand surges. By holding secure raw material inventory, we buffer against market shortages and help regular customers maintain workflow stability even under supply chain pressure. We monitor raw material pipeline risks proactively; our responsibility does not stop at finished goods—stability starts with disciplined raw materials procurement and ends only after the cargo reaches your dock.
Direct engagement with the manufacturer offers clear, reliable information about real production steps, shipment timeframes, and total cost of supply. There are no hidden third-party markups or vague delivery promises. Our clients leverage this transparency to better plan their own procurement and inventory cycles with fewer surprises and delays, assured by our commitment to every order, batch, and delivery from our own factory floor.
Shipping amino acid additives like Alanyl Glutamine across borders brings a distinct set of responsibilities. Direct from our production line, we always pay attention to both regulatory compliance and efficient movement through international freight channels. Alanyl Glutamine, by its very chemical nature and as confirmed through our quality assurance practices, does not fall into hazardous cargo categories under major international frameworks such as IATA DGR, IMDG, or ADR. Our shipping documentation, generated in-house, states clearly that Alanyl Glutamine is a non-dangerous good. This status speeds up transport logistics and streamlines communication with freight handlers.
Factory safety procedures start from raw material selection and continue through to final packaging. Our team understands that chemical handling practices must match up with both local and international guidelines. We carry out site-specific hazardous assessments during each production batch, ensuring that our safety precautions remain practical for every stage of the process. Alanyl Glutamine itself presents a low risk during normal handling and poses no flammability or reactive hazard. Nevertheless, our warehouse staff and logistics partners rely on clear product labels and safety fact sheets to ensure safe routine operations.
Any discussion about international transport inevitably circles back to traceability and technical documentation. We provide a full Material Safety Data Sheet (MSDS) tailored for Alanyl Glutamine, prepared and regularly reviewed by our technical experts. Our MSDS follows the requirements set out by GHS (Globally Harmonized System) and meets the documentation standards used by most regulatory authorities worldwide. Customers and shipping agents alike receive the MSDS and other technical documents with each shipment and upon request.
The Certificate of Analysis carries weight in confirming shipment integrity and compliance. Every lot of Alanyl Glutamine leaves our facility with a batch-specific CoA. Our on-site laboratory tests key parameters—purity, identification, appearance, and loss on drying—against both the current pharmacopeia and the specific requirements of our customers. Copies of the CoA go directly to regulatory personnel for customs clearance and to QA teams downstream in the supply chain.
Global markets move quickly, and logistics requirements shift alongside new regulations. Our regulatory affairs department tracks updates from global and regional transit authorities, evaluating how changing rules might affect the way we document, package, and ship Alanyl Glutamine. Periodic audits and inspections reinforce our confidence in the routines that minimize risk and eliminate unnecessary transport delays. Where customer requirements call for additional testing or unique transport documentation, we coordinate internally to address these cases on a fact-based, practical basis.
Buyers and partners require more than just product quality; they look for full transparency in documentation and an open approach to compliance. As the direct manufacturer, we give our clients immediate access to technical support and regulatory documentation, including digital copies for pre-clearance and hard copies with the shipment. This policy keeps supply chains predictable, supports timely delivery, and reflects our factory's commitment to both quality and safety from manufacture through to end use.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
